Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT02269982 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT02269982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02269982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Lead sponsor
Duke University
Phase
Observational
Overall status
Completed
Start date
May 14, 2015
Completion date
April 30, 2019
Enrollment
120 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer